Symphony Therapeutics to Debut Uses of Novel LNP Platform at 2024 TechConnect World Innovation Conference

Bedford, MA – Jun 4, 2024. Symphony Therapeutics, a subsidiary of Integral BioSystems, is set to revolutionize ophthalmic drug delivery with its OcuHeal™ LNP platform. Dr. Shikha Barman will present this cutting-edge technology at the 27th Annual TechConnect World Innovation Conference and Expo on June 18, 2024. The OcuHeal™ LNP platform, patented globally, is designed for multiple indications in ophthalmology and dermatology. The presentation, titled “OcuHeal UV-400+: Ophthalmic, UV-blocking, Anti-oxidant, Preservative-free Nanolipid Eye-drop,” will be held at Booth #709 at the Gaylord National Convention Center in National Harbor, Maryland.

OcuHeal™ LNP addresses the challenge of poor drug absorption in traditional ophthalmic formulations, which often results in less than 5% of the drug being absorbed by the target tissue. By utilizing nanostructured emulsions that release the drug at the requisite tissue site, OcuHeal™ LNP allows for a significantly lower drug dosage with equivalent or improved therapeutic effects. Symphony Therapeutics is actively developing an ophthalmic pipeline based on this technology and seeks licensing collaborations for additional applications in ophthalmic, dermal, and other routes that can benefit from this innovative platform.

If interested to know more, please email at bizdev@symphonytx.com. Symphony Therapeutics was founded in July 2022, as a wholly-owned subsidiary of Integral BioSystems.

Contract Research Organization

Serving bio-pharmaceutical companies since 2011

Integral BioSystems offers quality, high-end R&D and cGLP technical services in specialty drug formulation development services for a variety of dosage forms.